De novo acute myeloid leukemia with inv(3)(q21q26.2) or t(3;3)(q21;q26.2): A clinicopathologic and cytogenetic study of an entity recently added to the WHO classification

Modern Pathology

Volumn 24, Issue 3, 2011, Pages 384-389

  Sun, Jianlan ^a   Konoplev, Sergej N ^a   Wang, Xuemei ^a   Cui, Wei ^a   Chen, Su S ^a   Medeiros, L Jeffrey ^a   Lin, Pei ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

acute myeloid leukemia; EVI1; inv(3)

Indexed keywords

ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; DISEASE CLASSIFICATION; DYSPLASIA; FEMALE; GENE MUTATION; HUMAN; KARYOTYPE; MALE; MONOSOMY 7; MYELOMONOCYTIC LEUKEMIA; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOSIS; WORLD HEALTH ORGANIZATION;

EID: 79952194399     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2010.210     Document Type: Article

References (18)

1. Arber DA, Brunning R, Le Beau MM, et al. Acute myeloid leukemia with recurrent genetic abnormalities In: Swerdlow SH, Campo E, Harris NL, et al (eds). World Health Organization Classification of Tumors of Haematopoietic and Lymphoid Tissues, 4th edn. WHO Press: Geneva, Switzerland, 2008, pp 116-117.
2. 0 of the ribophorin I gene at 3q21 associated with the transcriptional activation of the EVI1 gene in acute myelogenous leukemias with inv(3)(q21q26). Blood 1994;84:2681-2688.
3. Buonamici S, Li D, Chi Y, et al. EVI1 induces myelodys-plastic syndrome in mice. J Clin Invest 2004;114:713-719. (Pubitemid 39582822)
4. Weisser M, Haferlach C, Haferlach T, et al. Advanced age and high initial WBC influence the outcome of inv(3)(q21q26)/t(3;3) (q21;q26) positive AML. Leuk Lymphoma 2007;48:2145-2151. (Pubitemid 350107691)
5. Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities amongst 5876 younger adult patients treated in the UK Medical Research Council trials. Blood 2010;116:354-365.
6. Reiter E, Greinix H, Rabitsch W. et al. Low curative potential of bone marrow transplantation for highly aggressive acute myelogenous leukemia with inver-sioin inv(3)(q21q26) or homologous translocation t(3;3)(q21;q26). Ann Hematol 2000;79:374-377. (Pubitemid 30459662)
7. Bitter MA, Neilly ME, Le Beau MM, et al. Rearrangements of chromosome 3 involving bands 3q21 and 3q26 are associated with normal or elevated platelet counts in acute nonlymphocytic leukemia. Blood 1985;66:1362-1370. (Pubitemid 16194700)
8. Jotterand Bellomo M, Parlier V, Muhlematter D, et al. Three new cases of chromosome 3 rearrangement in bands q21 and q26 with abnormal thrombopoiesis bring further evidence to the existence of a 3q21q26 syndrome. Cancer Genet Cytogenet 1992;59:138-160.
9. Lin P, Chen L, Luthra R, et al. Acute myeloid leukemia harboring t(8;21)(q22;q22): a heterogeneous disease with poor outcome in a subset of patients unrelated to secondary cytogenetic aberrations. Mod Pathol 2008;21:1029-1036.
10. Lin P, Jones D, Medeiros LJ, et al. Activating FLT3 mutations are detectable in chronic and blast phase of chronic myeloproliferative disorders other than chronic myeloid leukemia. Am J Clin Pathol 2006;126:530-533. (Pubitemid 44498502)
11. Kilbey A, Alzuherri H, McColl J, et al. The evi1 proto-oncoprotein blocks endomitosis in megakaryocytes by inhibiting sustained cyclin-dependent kinase 2 catalytic activity. Br J Haematol 2005;130:902-911. (Pubitemid 43899731)
12. Morishita K, Parker DS, Mucenski ML, et al. Retroviral activation of a novel gene encoding a zinc finger protein in IL-3-dependent myeloid leukemia cell lines. Cell 1988;54:831-840.
13. Goyama S, Kurokawa M. Pathogenetic significance of ecotropic viral integration site-1 in hematological malignancies. Cancer Sci 2009;100:990-995.
14. Goyama S, Yamamoto G, Shimabe M, et al. Evi-1 is a critical regulator for hematopoietic stem cells and transformed leukemic cells. Cell Stem Cell 2008;3:207-220.
15. Groschel S, Lugthart S, Schlenk RF, et al. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. J Clin Oncol 2010;28:2101-2107.
16. Lugthart S, van Drunen E, van Norden Y, et al. High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. Blood 2008;111:4329-4337.
17. Stein S, Ott MG, Schultze-Strasser S, et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 2010;16: 198-204.
18. Bouscary D, Fontenay-Roupie M, Chretien S, et al. Thrombopoietin is not responsible for the thrombocytosis observed in patients with acute myeloid leukemias and the 3q21q26 syndrome. Br J Haematol 1995;91:425-427.